Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

NCT06561620 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

592

Enrollment

OTHER

Sponsor class

Conditions

3-year Disease-free Survival

Interventions

DRUG: Befotertinib

Sponsor

Fudan University